Media stories about Laboratory Corporation of America Holdings (NYSE:LH) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Laboratory Corporation of America Holdings earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 46.3603538063193 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
- LabCorp Reports New Use of Agilent’s Cancer Diagnostic Test (nasdaq.com)
- Laboratory of America : Cority Enhances Clinical Testing Solution with LabCorp Interface (4-traders.com)
- LabCorp Announces New Expanded Use for PD-L1 Test with Bristol-Myers Squibb’s OPDIVO® (finance.yahoo.com)
- Laboratory Corp. of America Holdings : Earnings Review and Free Research Report: Labcorp’s Revenue Jumped 9.5%; Raised Outlook for 2017 (4-traders.com)
- LabCorp firm partners with Canadian company to offer diagnostic tests for medical marijuana (finance.yahoo.com)
Laboratory Corporation of America Holdings (LH) traded down $0.66 during mid-day trading on Monday, hitting $150.36. 468,500 shares of the stock were exchanged, compared to its average volume of 719,423. The company has a market cap of $15,400.00, a PE ratio of 16.17, a PEG ratio of 1.59 and a beta of 0.87. The company has a quick ratio of 1.75, a current ratio of 1.89 and a debt-to-equity ratio of 1.18. Laboratory Corporation of America Holdings has a one year low of $123.36 and a one year high of $164.22.
Laboratory Corporation of America Holdings (NYSE:LH) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.46 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.38 by $0.08. The company had revenue of $2.60 billion for the quarter, compared to analysts’ expectations of $2.55 billion. Laboratory Corporation of America Holdings had a net margin of 7.40% and a return on equity of 16.75%. The business’s revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.25 EPS. research analysts forecast that Laboratory Corporation of America Holdings will post 9.53 EPS for the current year.
A number of research firms recently weighed in on LH. Barclays PLC increased their price objective on Laboratory Corporation of America Holdings from $183.00 to $190.00 and gave the company an “overweight” rating in a report on Thursday, October 26th. Zacks Investment Research downgraded Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a report on Friday, October 27th. Jefferies Group LLC restated a “hold” rating and issued a $170.00 price objective (up from $157.00) on shares of Laboratory Corporation of America Holdings in a report on Wednesday, September 13th. Morgan Stanley increased their price objective on Laboratory Corporation of America Holdings from $154.00 to $166.00 and gave the company an “overweight” rating in a report on Thursday, August 10th. Finally, Canaccord Genuity restated a “buy” rating and issued a $180.00 price objective (up from $175.00) on shares of Laboratory Corporation of America Holdings in a report on Monday, September 11th. Seven research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $169.00.
WARNING: This report was posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.truebluetribune.com/2017/11/20/laboratory-corporation-of-america-holdings-lh-given-daily-coverage-optimism-score-of-0-12.html.
In related news, insider F Samuel Eberts III sold 31,500 shares of the firm’s stock in a transaction dated Friday, August 25th. The shares were sold at an average price of $155.22, for a total value of $4,889,430.00. Following the transaction, the insider now owns 31,894 shares of the company’s stock, valued at approximately $4,950,586.68. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Dwight Gary Gilliland sold 971 shares of the firm’s stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $153.52, for a total transaction of $149,067.92. Following the completion of the transaction, the director now directly owns 3,501 shares in the company, valued at approximately $537,473.52. The disclosure for this sale can be found here. Insiders have sold a total of 209,871 shares of company stock worth $32,892,005 in the last three months. Insiders own 0.90% of the company’s stock.
Laboratory Corporation of America Holdings Company Profile
Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).
Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with MarketBeat.com's FREE daily email newsletter.